



Original Scientific Article

EVALUATION OF SOME INTESTINAL MUCOSAL EPITHELIAL BARRIER
DAMAGE BIOMARKERS IN DOGS WITH GIARDIASIS

Murat Kaan Durgut, Mahmut Ok, Merve Ider, Amir Naseri, Yusuf Emre Ekici,
Suleyman Serhat Iyigun, Nimet Ismailoglu, Rumeyhisa Ozlem Bicici

Department of Internal Medicine, Faculty of Veterinary Medicine, Selçuk University,
Konya 42003, Türkiye

Received 13 November 2024; Received in revised form 1 March 2025; Accepted 18 June 2025

ABSTRACT

Giardia intestinalis is a parasitic protozoan commonly seen in dogs and causes intestinal mucosal barrier damage. In this study, serum intestinal fatty acid binding protein (I-FABP), intestinal alkaline phosphatase (IAP), and intestinal trefoil factor-3 (TFF-3) concentrations were assessed in *Giardia intestinalis*-infected dogs to determine their association with intestinal mucosal epithelial barrier damage and their potential to be used as a non-invasive diagnostic method. The study was conducted on 39 dogs (26 with giardiasis and 13 healthy dogs) of different breeds and sex. Giardiasis was diagnosed from fecal samples by rapid antigen test kit and fecal flotation test. Serum I-FABP ($p=0.024$), IAP ($p=0.04$), and TFF-3 ($p=0.028$) levels were significantly higher in dogs with giardiasis compared to the healthy group. These findings indicate that *Giardia* infection causes damage to the intestinal mucosa which triggers release of these compounds as protective mechanism. The positive correlation between the biomarkers and the giardiasis infection in dogs, indicate that they could be used as a non-invasive diagnostic method.

Key words: *Giardia*, dogs, I-FABP, IAP, TFF-3

INTRODUCTION

Giardia intestinalis (*Giardia duodenalis*, *Giardia lamblia*) is a flagellated protozoan that causes giardiasis, one of the most common parasitic infections in dogs and other mammals worldwide (1, 2). The prevalence of *Giardia intestinalis* in dogs has been reported to range from 1.6 to 100% in different geographical regions (1). Giardiasis is characterized by various clinical forms, ranging from asymptomatic infection to acute and chronic disease. Symptoms vary depending on many factors such as the age of the host, history of previous infections, parasite load, virulence of the parasite, and host immune response (3). Although

the disease has been known for at least a hundred years, its significance has grown in recent years due to the increasing number of pet animals and the zoonotic potential outcomes (4).

The life cycle of giardiasis is important in terms of understanding the pathogenesis of the disease and the development of intestinal mucosal damage. There are two main stages in the life cycle of *Giardia intestinalis*. The first of these stages is excystation, where the transformation from cyst form to trophozoite form occurs, and the second stage is encystation, where the transition from trophozoite form to cyst form occurs (5). Cysts are usually ingested by the host with contaminated food and water (6). In the host, gastric acids metabolically activate the cysts and the excystation process starts with a sudden decrease in pH and hydrogen ion flow. In the host, the cysts open and are completely excreted in the duodenum and jejunum with the help of secreted bile and proteases, thus trophozoite formation begins (3). *Giardia intestinalis* trophozoites strongly adhere to the epithelial surface of the intestine via the ventral adhesive disc (7). Adhesion of trophozoites to epithelial cells causes shortening of microvilli,

Corresponding author: Dr. Murat Kaan Durgut, PhD
E-mail address: mkaan.durgut@selcuk.edu.tr
Present address: Department of Internal Medicine, Faculty of
Veterinary Medicine, Selçuk University, Konya 42003, Türkiye
Phone: +90 539 477 88 19

Copyright: © 2025 Durgut M.K. This is an open-access article published under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors have declared that no competing interests exist.

Available Online First: 2 July 2025

Published on: 15 October 2025

<https://doi.org/10.2478/macvetrev-2025-0024>

which targets specific signaling networks that can activate apoptosis. This leads to loss of intercellular junctions that contribute to diarrhea, cytoskeletal reorganization and epithelial barrier dysfunction (8). Histopathological findings in giardiasis include villous atrophy, microvillous shortening, decreased disaccharidase activity, loss of epithelial barrier function, increased intestinal permeability and intestinal mucosal epithelial barrier damage (9). While intestinal mucosal epithelial barrier damage can usually be determined by invasive methods such as biopsy, recent studies in veterinary medicine have demonstrated the utility of biomarkers such as intestinal fatty acid binding protein (I-FABP), intestinal alkaline phosphatase (IAP), intestinal trefoil factor-3 (TFF-3), to assess intestinal mucosal epithelial barrier damage caused by various diseases (10, 11, 12, 13). These biomarkers are released from intestinal tissue into the bloodstream when the intestinal mucosal epithelial barrier is damaged, thus providing potential diagnostic utility for assessing intestinal mucosal epithelial barrier damage (14, 15, 16). In addition to their diagnostic role in determining epithelial damage, these biomarkers, such as IAP and TFF-3, also demonstrate cytoprotective effects by reducing and repairing intestinal damage (15).

This study was designed with the hypothesis that intestinal mucosal epithelial barrier damage in *Giardia intestinalis* infected dogs could be determined by I-FABP, IAP, TFF-3 biomarkers. The aim of this study was to assess a non-invasive method for detection of intestinal mucosal epithelial barrier damage in dogs caused by *Giardia intestinalis* with intestinal damage biomarkers.

MATERIAL AND METHODS

The study was conducted in the period between January and July 2023. It included 39 dogs admitted at the Small Animal Hospital, Faculty of Veterinary Medicine, Selcuk University. The study protocol was approved by the Institutional Ethics Committee at the Faculty of Veterinary Medicine, Selcuk University (No. 2023/035). A statement had been obtained from all dog owners confirming their consent for the samples to be used for scientific purposes.

Dogs with giardiasis

The experimental group was comprised of 26 owned dogs naturally infected with *Giardia* admitted at the clinic with signs of diarrhea.

Physical examination findings, age, breed, sex, and fecal consistency were recorded. There were 14 male and 12 female dogs, aged between 2 months and 4 years. The distribution among breeds was 5 Kangal, 4 Golden Retrievers, 3 Rottweilers, 3 German Shepherds, 2 Terriers, 1 Cavalier King Charles, and 8 mixed breeds. Giardiasis was diagnosed by Zinc Sulphate Flotation technique in the parasitology laboratory (17).

Healthy dogs

The healthy group was comprised of 13 healthy dogs of the same age range (2 months to 4 years). They were admitted at the faculty clinic for routine vaccination. There were 8 male and 5 female dogs. The distribution among breeds was 3 Kangals, 2 Golden Retrievers, 2 Terriers, 1 German Shepherd, and 5 mixed breeds. The dogs underwent a complete physical examination and fecal analysis was conducted to ensure that they were healthy before inclusion in the study. The fecal samples were collected and analyzed in three consecutive days due to the intermittent spread of giardiasis. Samples with no findings of *Giardia* cysts on the three consecutive analyses, were considered negative.

Inclusion and exclusion criteria

Dogs with combined infestation confirmed by coproparasitological analysis, including giardiasis and other parasitic diseases (toxocariasis, isosporiasis, etc.), and dogs that were seropositive for Parvovirus or Coronavirus (Asan Easy Test Corona Parvo®, Asan Pharmaceutical, Korea), were not included in the study. In addition, animals treated with antiparasitic drugs for at least 3 weeks prior the study, were not included.

As described earlier, negative findings of *Giardia* cysts in three consecutive fecal samples and negative coprological and serological finding of other parasitic and/or viral infections, were inclusion criteria for the healthy group.

Collection of fecal samples

About 5 g of fecal samples were collected directly from the rectum of the dogs and were placed in two different fecal containers. One of the fecal samples was sent to the laboratory at the Department of Parasitology, Faculty of Veterinary Medicine, Selcuk University for coproparasitological analysis (native examination and flotation). The other part was screened for Parvovirus and Coronavirus with a rapid antigen test kit (Asan Easy Test Corona Parvo®, Asan Pharmaceutical, Korea).

Collection of blood samples

Blood samples from the healthy and *Giardia intestinalis* positive dogs were collected from the cephalic vein at the time of admission into 8 mL vacuum serum tubes. The serum samples were centrifuged at 2,000 g for 5 min after clotting. The serum was removed and stored at -80 °C until analysis.

Biomarker analyses

Serum I-FABP, TFF-3, IAP concentrations (Bioassay Technology Laboratory Co., Zhejiang, China) were measured with commercial canine-specific ELISA test kits according to the manufacturer's instructions. Canine I-FABP commercial ELISA kit (Bioassay Technology Laboratory Co., Zhejiang China Cat. No: E0304Ca), Canine TFF-3 commercial ELISA kit (Bioassay Technology Laboratory Co., Zhejiang China Cat. No: E0305Ca), and Canine IAP commercial ELISA kit (Bioassay Technology Laboratory Co., Zhejiang China Cat. No: E0438Ca) were used for ELISA analyses of biomarkers. The intra-assay coefficient of variation (CV), inter-assay CV, and minimum detectable concentrations (MDC) for biomarkers were <8%, <12%, 0.12 ng/mL for I-FABP, <8%, <10%, 0.29 ng/mL for TFF-3, <8%, <10%, 0.26 ng/mL for IAP, respectively.

Statistical analysis

SPSS 25 (IBM Corp®, 2017, Armonk, NY, USA) statistical program was used to evaluate the data. One Sample Kolmogorov-Smirnov test was applied to evaluate the prerequisites for normal distribution (parametric or non-parametric) of the data. The study data showed parametric distribution and were evaluated using Student's t-test, they were presented as mean ± SD. The Cohen's d was calculated to determine the effect size. The power of each

analysis was calculated based on Cohen's d values with a threshold of 0.95. The Pearson correlation test was used to determine the correlation between variables. Statistical significance was considered as $p < 0.05$.

RESULTS

Clinical findings

Dogs with giardiasis included in the study had watery-mucous diarrhea for several days. They had decreased appetite and mild to moderate dehydration.

Biomarker findings

Intestinal biomarker findings of healthy and dogs with giardiasis are presented in Table 1. Serum I-FABP (Cohen's $d=0.73$, 95% Confidence interval (CI): -2.8, -0.2), IAP ($d=0.87$, 95% CI: -9.82, -2.01), TFF-3 ($d=0.33$, 95% CI: -3.8, 1.15) concentrations were higher in dogs with giardiasis compared to the healthy group ($p < 0.05$). Serum I-FABP concentrations were minimum 3.44 ng/mL and maximum 5.88 ng/mL in the healthy group and minimum 5.42 ng/mL and maximum 13.55 ng/mL in the giardiasis group. Serum IAP concentrations were minimum 2.75 ng/mL and maximum 10.75 ng/mL in the healthy group and minimum 20.75 ng/mL and maximum 37.32 ng/mL in the giardiasis group. Serum TFF-3 concentrations were minimum 4.35 ng/mL and maximum 8.86 ng/mL in the healthy group and minimum 7.06 ng/mL and maximum 22.03 ng/mL in the giardiasis group.

Correlation analysis findings between serum biomarker concentrations are presented in Table 2. A positive correlation was found between serum I-FABP and IAP ($r=.905$), TFF-3 ($r=.669$) concentrations ($p < 0.01$).

Table 1. Comparison of serum intestinal biomarker concentrations in healthy and dogs with giardiasis

Variable	Healthy (n=13)	Giardiasis (n=26)	p value	Cohen's d	Power analysis	95% confidence interval of the difference	
						Lower	Upper
I-FABP (ng/mL)	6.14±1.26 (3.44-5.88)	7.69±2.70 (5.42-13.55)	0.024	0.732691	0.55602	-2.878	-0.218
IAP (ng/mL)	5.88±2.10 (2.75-10.75)	11.80±9.28 (20.75-37.32)	0.004	0.878876	0.71217	-9.823	-2.010
TFF-3 (ng/mL)	9.16±2.65 (4.35-8.86)	10.49±4.99 (7.06-22.03)	0.028	0.332447	0.15887	-3.817	1.155

I-FABP (intestinal fatty acid binding protein), IAP (intestinal alkaline phosphatase), TFF-3 (intestinal trefoil factor-3)
Serum intestinal biomarker concentrations are expressed as mean±SD and min-max in parenthesis

Table 2. Correlation between serum intestinal biomarker concentrations

Intestinal damage biomarkers	I-FABP	IAP	TFF-3
I-FABP	1	.905**	.669**
IAP		1	.532**
TFF-3			1

I-FABP (intestinal fatty acid binding protein), IAP (intestinal alkaline phosphatase), TFF-3 (intestinal trefoil factor-3)
Significant correlations ($p < 0.01$) are marked with **

DISCUSSION

The current study assessed I-FABP, IAP, and TFF-3 as biomarkers of intestinal damage in dogs positive on giardiasis. Our results showed that serum I-FABP, IAP, and TFF-3 levels may be useful diagnostic markers in the evaluation of intestinal mucosal epithelial barrier damage in dogs with giardiasis.

Intestinal fatty acid binding proteins (I-FABP) are cytosolic protein molecules synthesized by enterocytes particularly in the duodenum, jejunum, ileum, and colon (18). The function of I-FABP in intestinal enterocytes is to support their energetic homeostasis and to transport long-chain fatty acids (19). In healthy humans and animals, I-FABP is released into the bloodstream at very low or undetectable concentrations, whereas when intestinal mucosal damage develops, it begins to be released into the bloodstream in high concentrations (20). Increased serum I-FABP concentrations have been reported in humans with inflammatory bowel disease (21), celiac disease (22), giardiasis (23), and acute intestinal necrosis (24) due to intestinal mucosal damage. Serum I-FABP concentrations in calves have been reported to be higher than healthy calves in cases of atresia coli (12), neonatal enteritis (14), and coccidiosis (15). Additionally, I-FABP is a useful biomarker in determining intestinal damage in dogs with parvoviral enteritis (13, 25) and isosporiasis (10). In this study, serum I-FABP concentrations were higher in dogs with giardiasis compared to the healthy group ($p < 0.05$). These results were associated with increased release of I-FABP into the blood due to intestinal mucosal epithelial barrier damage during the life cycle of *Giardia intestinalis* (15, 23).

Intestinal alkaline phosphatase (IAP) is released from the apical microvilli of enterocytes into the intestinal lumen and has been shown to be an important factor in protection from

mucosal damage by regulating intestinal surface pH, absorption of lipids, detoxification of free nucleotides and bacterial lipopolysaccharide, and reduction of intestinal inflammation (26, 27). Intestinal alkaline phosphatase detoxifies bacteria by dephosphorylation and thus plays an anti-inflammatory role during intestinal inflammation (28). Studies on necrotizing enterocolitis have demonstrated that IAP-enriched nutrition reduces intestinal mucosal epithelial barrier damage and inflammatory cytokine release, confirming the anti-inflammatory and protective effects of IAP in the intestines (29, 30). Serum IAP concentrations have been reported to be higher in calves with atresia coli (11), and those with neonatal enteritis (14) compared to healthy calves. Similarly, serum IAP concentrations in dogs with isosporiasis (10) were higher than those in healthy dogs. Studies in Chron's disease have reported that low IAP concentrations result in high mucosal damage (31, 32). In contrast to these studies, serum IAP concentrations have not been shown to be useful in determining intestinal mucosal epithelial barrier damage in calves with coccidiosis (15). In the present study, serum IAP concentrations were higher in dogs with giardiasis compared to healthy dogs ($p < 0.05$). High serum IAP concentrations in dogs with giardiasis have been associated with intestinal mucosal epithelial barrier damage and increased release to reducing/healing the damage (26, 27).

Intestinal trefoil factor is polypeptide secreted by mucus cells in the intestine. These peptides are known to be cytoprotective and promote healing gastrointestinal damage (33). Elevated concentrations of TFF-3 have been reported in infants with necrotizing enterocolitis (34), and in humans with ulcerative colitis (35) in response to mucosal damage. Serum TFF-3 concentration was found to be increased in both dogs with parvoviral enteritis (13) and calves with neonatal enteritis (14). It was reported that serum TFF-3 concentrations

did not differ before treatment in dogs with isosporiasis (10) and calves with coccidiosis (15). However, they were increased after the treatment due to increased mucosal damage repair. In the present study, serum TFF-3 concentrations were higher in dogs with giardiasis compared to those in healthy dogs ($p < 0.05$). These results indicate the presence of giardiasis-associated mucosal damage in the intestines. The increased TFF-3 serum concentrations have been additionally associated with its higher release from tissues as a cytoprotective response (34, 35).

The simultaneous increase in serum concentrations of intestinal damage biomarkers (I-FABP, IAP, and TFF-3) (Table 1) and their strong in-between correlation (Table 2, $p < 0.01$) indicate that they are highly associated with the ongoing intestinal damage during giardiasis as a protective response.

The present study has some limitations. The high concentration of biomarkers observed in dogs with giardiasis suggests the presence of intestinal epithelial barrier damage and highlights the relationship between diarrhea and intestinal damage. However, for more accurate assessment of the association between biomarker levels, the severity of intestinal damage, and the severity of diarrhea, additional data could be introduced in the overall analysis such as patient follow-up, fecal scoring, and a larger sample size. In addition, the biomarkers of intestinal epithelial barrier damage have been evaluated in numerous studies, but the lack of histopathological confirmation of intestinal damage can be considered as a deficiency. Another limitation is the statistical power of the analyses. Power calculations based on Cohen's d values showed that all comparisons had power values below the recommended threshold of 0.95, suggesting that the sample size may not have been sufficient to detect smaller effect sizes with high confidence. Future studies with larger sample sizes and histopathological validation are recommended to further investigate the relationship between intestinal biomarkers and giardiasis-induced mucosal damage.

CONCLUSION

In conclusion, I-FABP, IAP, and TFF-3 concentrations were higher in dogs with giardiasis compared to the healthy group of dogs. Hence, these biomarkers can be considered as an effective and non-invasive method for detecting intestinal mucosal damage in dogs with giardiasis.

CONFLICT OF INTEREST

The authors declare that they have no financial or non-financial conflict of interest regarding authorship and publication of this article.

ACKNOWLEDGMENTS

The research was supported by the Veterinary Faculty at Selçuk University in Konya.

AUTHORS' CONTRIBUTION

MKD, YEE, SSI, NI and ROB made the data curation. MKD, MO, MI and AN wrote the original draft, contributed to conceptualization, design, methodology, writing, and editing of the manuscript.

REFERENCES

1. Solarczyk, P., Majewska, A.C. (2010). A survey of the prevalence and genotypes of *Giardia duodenalis* infecting household and sheltered dogs. *Parasitol Res.* 106(5): 1015-1019.
<https://doi.org/10.1007/s00436-010-1766-5>
PMid:20155370
2. Boucard, A.S., Thomas, M., Lebon, W., Polack, B., Florent, I., Langella, P., Bermudez-Humaran, L.G. (2021). Age and *Giardia intestinalis* infection impact canine gut microbiota. *Microorganisms.* 9(9): 1862.
<https://doi.org/10.3390/microorganisms9091862>
PMid:34576757 PMCID:PMC8469385
3. Einarsson, E., Ma'ayeh, S., Svard, S.G. (2016). An update on *Giardia* and giardiasis. *Curr Opin Microbiol.* 34, 47-52.
<https://doi.org/10.1016/j.mib.2016.07.019>
PMid:27501461
4. Ballweber, L.R., Xiao, L.H., Bowman, D.D., Kahn, G., Cama, V.A. (2010). Giardiasis in dogs and cats: update on epidemiology and public health significance. *Trends Parasitol.* 26(4): 180-189.
<https://doi.org/10.1016/j.pt.2010.02.005>
PMid:20202906
5. Ortega-Pierres, M.G., Jex, A.R., Ansell, B.R.E., Svard, S.G. (2018). Recent advances in the genomic and molecular biology of *Giardia*. *Acta Trop.* 184, 67-72.
<https://doi.org/10.1016/j.actatropica.2017.09.004>
PMid:28888474
6. Adam, R.D. (2021). *Giardia duodenalis*: biology and pathogenesis. *Clin Microbiol Rev.* 34(4): e00024-19.
<https://doi.org/10.1128/CMR.00024-19>
PMid:34378955 PMCID:PMC8404698

7. Cotton, J.A., Beatty, J.K., Buret, A.G. (2011). Host-parasite interactions and pathophysiology in Giardia infections. *Int J Parasitol.* 41(9): 925-933.
<https://doi.org/10.1016/j.ijpara.2011.05.002>
PMid:21683702
8. Dixon, B.R. (2021). Giardia duodenalis in humans and animals - Transmission and disease. *Res Vet Sci.* 135, 283-289.
<https://doi.org/10.1016/j.rvsc.2020.09.034>
PMid:33066992
9. Thompson, R.C.A., Palmer, C.S., O'Handley, R. (2008). The public health and clinical significance of Giardia and Cryptosporidium in domestic animals. *Vet J.* 177(1): 18-25.
<https://doi.org/10.1016/j.tvjl.2007.09.022>
PMid:18032076 PMCID:PMC7128580
10. Yildiz, I.K., Ok, M. (2022). Investigation of biomarkers indicating intestinal damage in Isospora-infected dogs. *Hungar Vet J.* 144(2): 101-113. [In Hungarian]
11. Yildiz, R., Ok, M., Ider, M., Akar, A., Naseri, A., Koral, E. (2019). The changes in biomarkers for necrotising enterocolitis in premature calves with respiratory distress syndrome. *Vet Med.* 64(10): 440-447.
<https://doi.org/10.17221/37/2019-VETMED>
12. Yildiz, R., Ok, M., Ider, M., Aydin, U., Naseri, A., Parlak, K., Gulersoy, E. (2018). Evaluation of intestinal damage biomarkers in calves with atresia coli. *J Vet Res.* 62(3): 379-384.
<https://doi.org/10.2478/jvetres-2018-0054>
PMid:30584620 PMCID:PMC6295999
13. Gulersoy, E., Ok, M., Yildiz, R., Koral, E., Ider, M., Sevinc, M., Zhunushova, A. (2020). Assessment of intestinal and cardiac-related biomarkers in dogs with parvoviral enteritis. *Pol J Vet Sci.* 23(2): 211-219.
<https://doi.org/10.24425/pjvs.2020.133635>
PMid:32627989
14. Ok, M., Yildiz, R., Hatipoglu, F., Baspinar, N., Ider, M., Uney, K., Erturk, A., Durgut, M.K., Terzi, F. (2020). Use of intestine-related biomarkers for detecting intestinal epithelial damage in neonatal calves with diarrhea. *Am J Vet Res.* 81(2): 139-146.
<https://doi.org/10.2460/ajvr.81.2.139>
PMid:31985285
15. Durgut, M.K., Ok, M. (2023). Evaluation of some intestinal biomarkers in the determination of intestinal damage in calves with coccidiosis. *Trop Anim Sci J.* 46(2): 221-230.
<https://doi.org/10.5398/tasj.2023.46.2.221>
16. Ekici, Y.E., Ok, M. (2024). Investigation of the relationship between atopic dermatitis of dogs and intestinal epithelial damage. *Vet Med Sci.* 10(3): e1453.
<https://doi.org/10.1002/vms3.1453>
PMid:38648253 PMCID:PMC11034634
17. Foreyt, W.J. (2013). Veterinary parasitology reference manual. John Wiley & Sons
18. Coe, N.R., Bernlohr, D.A. (1998). Physiological properties and functions of intracellular fatty acid-binding proteins. *Biochim Biophys Acta.* 1391(3): 287-306.
[https://doi.org/10.1016/S0005-2760\(97\)00205-1](https://doi.org/10.1016/S0005-2760(97)00205-1)
19. Guzman-Guzman, I.P., Noguera-Torres, B., Zaragoza-Garcia, O., Navarro-Zarza, J.E., Briceno, O., Perez-Rubio, G., Falfan-Valencia, R., et al. (2022). The infection, coinfection, and abundance of intestinal protozoa increase the serum levels of IFABP2 and TNF- α in patients with rheumatoid arthritis. *Front Med.* 9, 846934.
<https://doi.org/10.3389/fmed.2022.846934>
PMid:35492365 PMCID:PMC9039364
20. Ludwig, E.K., Hobbs, K.J., McKinney-Aguirre, C.A., Gonzalez, L.M. (2023). Biomarkers of intestinal injury in colic. *Animals (Basel).* 13(2): 227.
<https://doi.org/10.3390/ani13020227>
PMid:36670767 PMCID:PMC9854801
21. Sarikaya, M., Ergul, B., Dogan, Z., Filik, L., Can, M., Arslan, L. (2015). Intestinal fatty acid binding protein (I-FABP) as a promising test for Crohn's disease: A preliminary study. *Clin Lab.* 61(1-2): 87-91.
<https://doi.org/10.7754/Clin.Lab.2014.140518>
PMid:25807642
22. Oldenburger, I.B., Wolters, V.M., Kardol-Hoefnagel, T., Houwen, R.H.J., Otten, H.G. (2018). Serum intestinal fatty acid-binding protein in the noninvasive diagnosis of celiac disease. *APMIS* 126(3): 186-190.
<https://doi.org/10.1111/apm.12800>
PMid:29383769
23. Cascais-Figueiredo, T., Austriaco-Teixeira, P., Fantinatti, M., Silva-Freitas, M.L., Santos-Oliveira, J.R., Coelho, C.H., Singer, S.M., Da-Cruz, A.M. (2020). Giardiasis alters intestinal fatty acid binding protein (I-FABP) and plasma cytokine levels in children in Brazil. *Pathogens.* 9(1): 7.
<https://doi.org/10.3390/pathogens9010007>
PMid:31861618 PMCID:PMC7169386
24. Straarup, D., Gotschalck, K.A., Christensen, P.A., Krarup, H., Lundbye-Christensen, S., Handberg, A., Thorlacius-Ussing, O. (2023). Exploring I-FABP, endothelin-1 and L-lactate as biomarkers of acute intestinal necrosis: a case-control study. *Scand J Gastroenterol.* 58(12): 1359-1365.
<https://doi.org/10.1080/00365521.2023.2229930>
PMid:37403410

25. Ay, C.D., Tuna, G.E., Asici, G.S.E., Ulutas, B., Voyvoda, H. (2022). Serum intestinal fatty acid-binding protein and calprotectin concentrations to assess clinical severity and prognosis of canine parvovirus enteritis. *Kafkas Univ Vet Fak Derg.* 28(1): 105-114.
26. Goldberg, R.F., Austen, W.G., Zhang, X.B., Munene, G., Mostafa, G., Biswas, S., McCormack, M., et al. (2008). Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. *Proc Natl Acad Sci U.S.A.* 105(9): 3551-3556.
<https://doi.org/10.1073/pnas.0712140105>
PMid:18292227 PMCID:PMC2265168
27. Kuhn, F., Adiliaghdam, F., Cavallaro, P.M., Hamarneh, S.R., Tsurumi, A., Hoda, R.S., Munoz, A.R., et al. (2020). Intestinal alkaline phosphatase targets the gut barrier to prevent aging. *JCI Insight.* 5(6): 134049.
<https://doi.org/10.1172/jci.insight.134049>
PMid:32213701 PMCID:PMC7213802
28. Martins, R.D.S., Kooi, E.M.W., Poelstra, K., Hulscher, J.B.F. (2023). The role of intestinal alkaline phosphatase in the development of necrotizing enterocolitis. *Early Hum Dev.* 183, 105797.
<https://doi.org/10.1016/j.earlhumdev.2023.105797>
PMid:37300991
29. Rentea, R.M., Liedel, J.L., Fredrich, K., Pritchard, K.T. Jr., Oldham, K.T., Simpson, P.M., Gourlay, D.M. (2013). Enteral intestinal alkaline phosphatase administration in newborns decreases iNOS expression in a neonatal necrotizing enterocolitis rat model. *J Pediatr Surg.* 48(1): 124-128.
<https://doi.org/10.1016/j.jpedsurg.2012.10.026>
PMid:23331804 PMCID:PMC5664149
30. Biesterveld, B.E., Koehler, S.M., Heinzerling, N.P., Rentea, R.M., Fredrich, K., Welak, S.R., Gourlay, D.M. (2015). Intestinal alkaline phosphatase to treat necrotizing enterocolitis. *J Surg Res.* 196(2): 235-240.
<https://doi.org/10.1016/j.jss.2015.02.030>
PMid:25840489 PMCID:PMC4578817
31. Molnar, K., Vannay, A., Szebeni, B., Banki, N.F., Sziksz, E., Cseh, A., Gyorffy, H., et al. (2012). Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. *World J Gastroenterol.* 18(25): 3254-3259.
32. Park, S.Y., Kim, J.Y., Lee, S.M., Chung, J.O., Seo, J.H., Kim, S., Kim, D.H., et al. (2018). Lower expression of endogenous intestinal alkaline phosphatase may predict worse prognosis in patients with Crohn's disease. *BMC Gastroenterol.* 18(1): 188.
<https://doi.org/10.1186/s12876-018-0904-x>
PMid:30558547 PMCID:PMC6296121
33. Thim, L. (1994). Trefoil peptides: a new family of gastrointestinal molecules. *Digestion.* 55(6): 353-360.
<https://doi.org/10.1159/000201165>
PMid:7705547
34. Ng, E.W.Y., Poon, T.C.W., Lam, H.S., Cheung, H.M., Ma, T.P.Y., Chan, K.Y.Y., Wong, R.P.O., et al. (2013). Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants. *Ann Surg.* 258(6): 1111-1118.
<https://doi.org/10.1097/SLA.0b013e318288ea96>
PMid:23470582
35. Srivastava, S., Kedia, S., Kumar, S., Mouli, V.P., Dhingra, R., Sachdev, V., Tiwari, V., et al. (2015). Serum human trefoil factor 3 is a biomarker for mucosal healing in ulcerative colitis patients with minimal disease activity. *J Crohns Colitis.* 9(7): 575-579.
<https://doi.org/10.1093/ecco-jcc/jjv075>
PMid:25964429